<DOC>
	<DOCNO>NCT02183584</DOCNO>
	<brief_summary>Investigation bioavailability linagliptin concomitant multiple oral administration 5 mg linagliptin tablets 600 mg rifampicin ( Treatment A ) comparison multiple oral administration 5 mg linagliptin tablet give alone ( Treatment B )</brief_summary>
	<brief_title>Study Evaluate Effect Multiple Doses Rifampicin Multiple-dose Pharmacokinetics Linagliptin Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age 18 50 year ( incl . ) BMI 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance Good clinical practice ( GCP ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic ( incl . porphyria ) , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackout . Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( 24 hour ) within least one month le 10 halflives respective drug prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( 10 cigarette 3 cigar 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 30 g/day male , 20 g/day female ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site Thrombocytopenia increase liver function test ( i.e . Alanine transaminase ( ALT ) , Aspartate transaminase ( AST ) , bilirubin , Alkaline phosphatase ( AP ) , Gammaglutamyl transferase ( GGT ) ) screen prior rifampicin exposure For female subject : Positive pregnancy test , pregnancy plan become pregnant study within 2 month study completion No adequate contraception study 1 month study completion , i.e . follow : IUD ( intrauterine device ) , sexual abstinence least 1 month prior enrolment , vasectomised partner ( vasectomy perform least 1 year prior enrolment ) , surgical sterilisation ( include hysterectomy ) . Females , vasectomise partner , sexually abstinent surgically sterile use additional barrier method ( e.g . condom , diaphragm spermicide ) Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>